|Bid||42.98 x N/A|
|Ask||43.25 x N/A|
|Day's Range||42.81 - 43.26|
|52 Week Range||35.75 - 46.83|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Feb.01 -- Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk A/S, the world's biggest maker of diabetes drugs, discusses earnings, the company's growth potential, pricing and a proposal by the administration of U.S. President Donald Trump to limit the discounts pharma companies pay middlemen that have been criticized for driving up costs for patients. Jorgensen speaks on "Bloomberg Markets: European Open."
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Shares of pharmaceutical companies Johnson & Johnson and Novo Nordisk popped Wednesday on bullish expectations for their diabetes treatments after the American Diabetes Association meeting.
Pharmaceutical company Novo Nordisk said Tuesday its experimental diabetes treatment proved safe in patients with heart disease. It could rival drugs from Lilly, AstraZeneca and Sanofi.
An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday. Patients with type 2 diabetics and either heart disease or at high risk for heart problems who received the drug semaglutide in pill form had a combined rate of heart attack, stroke or heart-related death of 3.8% compared with 4.8% for placebo, successfully demonstrating non-inferiortiy.
European stocks finished higher for a third day on Tuesday, as German shares caught up with a global stock rally after a holiday on easing trade tensions, while fresh stimulus for China's slowing economy boosted the basic resources sector. The pan-European STOXX 600 index closed at its highest level since May 17, with miners, auto stocks and chemical companies tacking on biggest gains after reports that Beijing was opening the door to more spending by local governments.
Eli Lilly announced positive results in a long-term trial of its diabetes drug Trulicity, but that doesn’t seem to have been enough for Wall Street.
in their efforts to help combat liver disease. The two companies said they will collaborate on clinical trials for medications for treating nonalcoholic steatohepatitis (NASH). "The intended clinical trial will be a proof of concept study," according to a press release from Gilead.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH. The clinical trial will be a study combining Novo Nordisk's semaglutide drug and Gilead's cilofexor and firsocostat for treatment of patients with Nonalcoholic steatohepatitis (NASH), Novo Nordisk, best known for its diabetes drugs, said on Friday.
COPENHAGEN (Reuters) - The chief executive of drugmaker Novo Nordisk on Friday welcomed a proposal calling for an end to the industry practice of offering after-market discounts called rebates to pharmacy ...
On a per-share basis, the Bagsvaerd, Denmark-based company said it had net income of 54 cents. The drugmaker posted revenue of $4.55 billion in the period. For the year, the company reported profit of ...
Novo Nordisk reported solid growth for its new diabetes drug on Friday and said it would submit a tablet version, a key growth hope, for U.S. approval in the first quarter, lifting the Danish drugmaker's shares. The world's top maker of diabetes drugs expects 2019 sales growth of 2-5 percent and operating profit growth of 2-6 percent, both measured in local currency. Novo faces pressure on prices from competitors and lawmakers in the United States and is pinning its growth hopes on a once-weekly injection and tablet version of its GLP-1 drug semaglutide for diabetes, as well as anti-obesity treatments.